Biovail Seeks To Block Generic Competiton For Wellbutrin XL

Law360, New York (September 27, 2005, 12:00 AM EDT) -- Biovail Laboratories International SRL has brought a lawsuit against Watson Laboratories Inc. in order to prevent the drug maker from marketing a generic form of the anti-depressant Wellbutrin XL.

Watson informed Biovail in a letter dated July 21, 2005 that it had filed an Abbreviated New Drug Application with the Food and Drug Administration in hopes of producing a generic version of Wellbutrin XL.

Biovail asked Watson to provide information about the drug that would allow the company to determine whether or not its patent had...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.